Experimental 'Off-the-Shelf' cell therapy targets Hard-to-Treat blood cancers
NCT ID NCT07506668
First seen Apr 04, 2026 · Last updated May 22, 2026 · Updated 5 times
Summary
This early-phase study tests a new treatment called RN1701 for people with B-cell lymphoma that has come back or stopped responding to standard therapy. RN1701 uses donor immune cells that are specially designed to find and attack cancer cells. The main goals are to check if the treatment is safe and to see if it can shrink tumors. About 10 to 19 participants will take part in this small, closely monitored study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.